Pregled bibliografske jedinice broj: 937281
A Phase II Study of Trastuzumab Plus Capecitabine with or Without Pertuzumab for HER2-positive Metastatic Breast Cancer as Second-line Treatment (PHEREXA)
A Phase II Study of Trastuzumab Plus Capecitabine with or Without Pertuzumab for HER2-positive Metastatic Breast Cancer as Second-line Treatment (PHEREXA) // European Journal of Cancer, Supplement 1
Beč, Austrija, 2012. str. 97-97 doi:10.1016/S0959-8049(12)70262-9 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 937281 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A Phase II Study of Trastuzumab Plus Capecitabine with or Without Pertuzumab for HER2-positive Metastatic Breast Cancer as Second-line Treatment (PHEREXA)
Autori
Urruticoechea, A ; Canney, P ; Separovic, R ; Bachelot, T ; Efran, J ; Canon, JL ; Martinez del Prado, P ; Barone, C ; Mayne, M ; Munoz, M
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
European Journal of Cancer, Supplement 1
/ - , 2012, 97-97
Skup
European Breast Cancer Conference
Mjesto i datum
Beč, Austrija, 21.03.2012. - 24.03.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
capecitabine ; pertuzumab ; trastuzumab ; breast cancer
Sažetak
Capecitabine in combination with trastuzumab is more efficacious than capecitabin alone as second-line treatment of patients with metastatic HER2-positive breast cancer
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
